LG Chem and Innovent Biologics side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | LG Chem | Innovent Biologics |
|---|---|---|
| Phase 1 | LG Chem: 2 of its 10 programs at phase 1 | Innovent Biologics: 14 of its 40 programs at phase 1
and 9 more — sign in to see them all |
| Phase 2 | LG Chem: 1 of its 10 programs at phase 2
| Innovent Biologics: 10 of its 40 programs at phase 2
and 5 more — sign in to see them all |
| Phase 3 | LG Chem: 4 of its 10 programs at phase 3
| Innovent Biologics: 15 of its 40 programs at phase 3
and 10 more — sign in to see them all |
| Approved, new studies | LG Chem: 3 of its 10 programs at approved, new studies
| Innovent Biologics: 1 of its 40 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LG Chem0 readouts · 0 phase 3 | · | · | · | · | · | · | · | · | · | · | · | · |
| Innovent Biologics18 readouts · 4 phase 3 | Innovent Biologics, Nov ’26: 1 program whose next study reaches primary completion
| Innovent Biologics, Dec ’26: 6 programs whose next study reaches primary completion, 3 in phase 3
and 1 more — sign in to see them all | Innovent Biologics, Jan ’27: 3 programs whose next study reaches primary completion
| Innovent Biologics, Feb ’27: 2 programs whose next study reaches primary completion
| Innovent Biologics, Mar ’27: 1 program whose next study reaches primary completion
| Innovent Biologics, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Innovent Biologics, May ’27: 1 program whose next study reaches primary completion
| Innovent Biologics, Jun ’27: 2 programs whose next study reaches primary completion
| Innovent Biologics, Jul ’27: 1 program whose next study reaches primary completion
| · | · | · |
Changed in the last 90 days
Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
LG Chem
New programs 0
None
Reached a new phase 1
- rilogrotugphase 3 · Oct 15 · Cachexia
Study stopped 0
None
Primary completion later 1
- rilogrotugphase 3 · Oct 2028 → Mar 2030 (+17 mo) · moved Oct 28 · NCT07888075
Innovent Biologics
New programs 4
- IBI3043phase 1 · first study · Oct 22
- IBI3034phase 1 · first study · Oct 8 · Glomerulonephritis, IGA
- telitaciceptphase 2 · first study · Sep 13 · Lupus Erythematosus, Systemic
- IBI3046phase 1 · first study · Sep 3 · Obesity
Reached a new phase 2
Study stopped 1
- IBI356phase 2 · terminated Oct 27 · none of its studies left running“Sponsor Decision” · NCT07330934
Primary completion later 1
- Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 2 · Mar 2026 → Dec 2026 (+9 mo) · moved Nov 2 · NCT06797297
Where they overlap
Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.
| Condition | LG Chem | Innovent Biologics |
|---|---|---|
| Obesityboth · compare here | Innovent Biologics in Obesity: 4 programs Their studies: Innovent Biologics’ studies of Obesity in search | |
| Diabetes Mellitus, Type 2both · compare here | LG Chem in Diabetes Mellitus, Type 2: 3 programs
Their studies: LG Chem’s studies of Diabetes Mellitus, Type 2 in search | Innovent Biologics in Diabetes Mellitus, Type 2: 1 program
Their studies: Innovent Biologics’ studies of Diabetes Mellitus, Type 2 in search |
| Renal Insufficiencyboth · compare here | LG Chem in Renal Insufficiency: 1 program
Their studies: LG Chem’s studies of Renal Insufficiency in search | Innovent Biologics in Renal Insufficiency: 3 programs
Their studies: Innovent Biologics’ studies of Renal Insufficiency in search |
| Breast Neoplasmsboth · compare here | LG Chem in Breast Neoplasms: 1 program
Their studies: LG Chem’s studies of Breast Neoplasms in search | Innovent Biologics in Breast Neoplasms: 1 program Their studies: Innovent Biologics’ studies of Breast Neoplasms in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.